Last updated: February 21, 2026
What is NDC 29300-0189?
NDC 29300-0189 is the National Drug Code for Dupixent (dupilumab), an injectable biologic medication approved for multiple allergic and inflammatory conditions. It is developed by Sanofi and Regeneron.
Market Overview
Therapeutic indications
Dupixent is approved for:
- Atopic dermatitis (moderate to severe)
- Asthma (moderate to severe eosinophilic or corticosteroid-dependent)
- Chronic rhinosinusitis with nasal polyposis
Market size
- Global biologic drugs market was valued at approximately USD 350 billion in 2022.
- Dupilumab contributed significantly, with estimates placing its sales at USD 6 billion in 2022.
Competitive landscape
Main competitors include:
- Sebrio (omalizumab)
- Xolair (omalizumab)
- Fasenra (benralizumab)
- Neulasta (pegfilgrastim) for some indications
The market for Dupixent is driven by its multiple indications, high efficacy, and favorable safety profile.
Adoption trends
- Steady growth in prescriptions for atopic dermatitis and asthma.
- Prescriptions increased by approximately 25% year-over-year from 2020 to 2022.
- Key markets: US, EU, Japan.
Price Analysis
Current pricing
- US: Wholesale Acquisition Cost (WAC) for Dupixent is approximately USD 3,000 per injection.
- Dosing varies by indication, typically 300 mg every other week.
| Price element |
Approximate cost |
| WAC per injection |
USD 3,000 |
| Average annual treatment cost (US) |
USD 36,000 based on biweekly dosing over 12 months |
| Out-of-pocket (estimated) |
USD 2,400 - USD 7,200 depending on insurance coverage |
International pricing
Pricing is lower outside the US, influenced by pricing regulations, healthcare policies, and negotiated discounts:
- EU countries: USD 2,000 - USD 2,500 per injection
- Japan: USD 2,200 per injection
Reimbursement landscape
- Widely reimbursed in developed markets.
- Prior authorizations often required.
- Value-based pricing models increasingly adopted, linking cost to patient outcomes.
Price Projection Factors
Patent expiry and biosimilar entry
- Patent expiration for Dupixent is expected around 2028-2030 in key markets.
- Biosimilar development is contingent on patent challenges but is unlikely to significantly impact market share before 2030.
Market growth projections
- Compound annual growth rate (CAGR) for Dupixent sales estimated at 12-15% through 2030, driven by expanding indications and geographic expansion.
- Sales forecast: USD 10 billion by 2025, USD 15 billion by 2028.
Pricing trends
- Anticipated stabilization or slight decrease in per-dose costs due to increased competition.
- Discounting strategies and value-based agreements may reduce net prices over time.
External factors
- Healthcare policy and pricing regulation changes in Europe and Asia.
- Entry of biosimilars could influence prices post-2030.
Summary of Price and Market Projections
| Year |
Projected Sales |
Projected Price per Injection |
Notes |
| 2023 |
USD 6 billion |
USD 3,000 |
Current market, US dominance |
| 2025 |
USD 10 billion |
USD 2,700 – USD 2,900 |
Growing markets in Asia, Europe, new indications |
| 2028 |
USD 15 billion |
USD 2,500 – USD 2,700 |
Patent expiry approaches, biosimilars likely |
Risks & Opportunities
- Risks: Patent cliffs, biosimilar entry, regulatory changes, pricing pressures.
- Opportunities: Expansion into new indications, geographic expansion, biosimilar development.
Key Takeaways
- NDC 29300-0189 (Dupixent) commands high prices in the US, with average annual costs around USD 36,000.
- Market size projected to reach USD 15 billion in sales by 2028, with growth driven by expanding indications and new markets.
- Price stabilization may occur post-2028 due to biosimilar entry and regulatory influences.
- Pricing strategies will adapt to reimbursement negotiations and market competition, with potential declines in net prices over the next five years.
FAQs
-
What is the primary indication for Dupixent?
Atopic dermatitis is the primary indication, accounting for the largest share of prescriptions.
-
How does Dupixent’s price compare internationally?
Prices outside the US are generally 20-30% lower, varying by country and healthcare policies.
-
When will biosimilars likely enter the market?
Biosimilar development is expected around 2028-2030, contingent on patent challenges and regulatory approvals.
-
What are the main factors driving future sales growth?
Expansion into new indications, increased patient access, and geographic expansion.
-
Will prices decrease significantly after patent expiry?
Biosimilar competition could lower prices, but the extent depends on market acceptance and regulatory factors.
References
[1] IQVIA. (2022). Biologics Market Review.
[2] EvaluatePharma. (2022). Global Oncology Biosimilars Market.
[3] U.S. Food and Drug Administration. (2022). Dupixent approval and patent timeline.
[4] European Medicines Agency. (2023). Pricing and reimbursement policies in Europe.
[5] GlobalData. (2023). Biologics Price and Market Forecasts.
